Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Nowogrodzka 59, 02-006, Warsaw, Poland.
Department of Urology, Medical University of Warsaw, Warsaw, Poland.
Stem Cell Res Ther. 2018 Sep 21;9(1):239. doi: 10.1186/s13287-018-0990-2.
Cell therapy constitutes an attractive alternative to treat stress urinary incontinence. Although promising results have been demonstrated in this field, the procedure requires further optimization. The most commonly proposed cell types for intraurethral injections are muscle derived cells (MDCs) and mesenchymal stem/stromal cell (MSCs). The aim of this study was to evaluate the effects of MDC-MSC co-transplantation into the urethra.
Autologous transplantation of labeled MDCs, bone marrow MSCs or co-transplantation of MDC-MSC were performed in aged multiparous female goats (n = 6 in each group). The mean number of cells injected per animal was 29.6 × 10(± 4.3 × 10). PBS-injected animals constituted the control group (n = 5). Each animal underwent urethral pressure profile (UPP) measurements before and after the injection procedure. The maximal urethral closure pressure (MUCP) and functional area (FA) of UPPs were calculated. The urethras were collected at the 28th or the 84th day after transplantation. The marker fluorochrome (DID) was visualized and quantified using in vivo imaging system in whole explants. Myogenic differentiation of the graft was immunohistochemically evaluated.
The grafted cells were identified in all urethras collected at day 28 regardless of injected cell type. At this time point the strongest DID-derived signal (normalized to the number of injected cells) was noted in the co-transplanted group. There was a distinct decline in signal intensity between day 28 and day 84 in all types of transplantation. Both MSCs and MDCs contributed to striated muscle formation if transplanted directly to the external urethral sphincter. In the MSC group those events were rare. If cells were injected into the submucosal region they remained undifferentiated usually packed in clearly distinguishable depots. The mean increase in MUCP after transplantation in comparison to the pre-transplantation state in the MDC, MSC and MDC-MSC groups was 12.3% (± 11.2%, not significant (ns)), 8.2% (± 9.6%, ns) and 24.1% (± 3.1%, p = 0.02), respectively. The mean increase in FA after transplantation in the MDC, MSC and MDC-MSC groups amounted to 17.8% (± 15.4%, ns), 15.2% (± 12.9%, ns) and 17.8% (± 2.5%, p = 0.04), respectively.
The results suggest that MDC-MSC co-transplantation provides a greater chance of improvement in urethral closure than transplantation of each population alone.
细胞疗法是治疗压力性尿失禁的一种有吸引力的替代方法。尽管在该领域已经取得了有希望的结果,但该过程需要进一步优化。最常被提议用于尿道内注射的细胞类型是肌肉来源的细胞(MDCs)和间充质干细胞/基质细胞(MSCs)。本研究的目的是评估将 MDC-MSC 共移植到尿道中的效果。
在年龄较大的多胎雌性山羊中进行自体移植标记的 MDC、骨髓 MSC 或 MDC-MSC 共移植(每组 n=6)。每只动物注射的细胞平均数量为 29.6×10(±4.3×10)。PBS 注射动物构成对照组(n=5)。每个动物在注射程序前后都进行尿道压力曲线(UPP)测量。计算 UPP 的最大尿道闭合压(MUCP)和功能区(FA)。在移植后第 28 天或第 84 天收集尿道。使用体内成像系统在整个外植体中可视化和量化标记荧光染料(DID)。通过免疫组织化学评估移植物的肌源性分化。
在第 28 天收集的所有尿道中均鉴定出移植的细胞,无论注射的细胞类型如何。在此时点,共移植组中观察到最强的 DID 衍生信号(相对于注射细胞的数量归一化)。在所有类型的移植中,从第 28 天到第 84 天,信号强度都明显下降。如果将 MSC 和 MDC 直接移植到尿道外括约肌,它们都会有助于形成横纹肌。在 MSC 组中,这种情况很少见。如果将细胞注射到黏膜下层区域,它们通常会保持未分化状态,并包装在可明显区分的隔室中。与移植前状态相比,MDC、MSC 和 MDC-MSC 组中移植后 MUCP 的平均增加分别为 12.3%(±11.2%,无显著性(ns))、8.2%(±9.6%,ns)和 24.1%(±3.1%,p=0.02)。MDC、MSC 和 MDC-MSC 组中移植后 FA 的平均增加分别为 17.8%(±15.4%,ns)、15.2%(±12.9%,ns)和 17.8%(±2.5%,p=0.04)。
结果表明,与单独移植每种细胞群体相比,MDC-MSC 共移植提供了更大的改善尿道闭合的机会。